title: Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
abstract: Fibrinolysis in acute myocardial infarction activates blood coagulation and may favor reocclusion or ischemic complications. The aim of the GUSTO V Italian Hematologic Substudy was to compare the effects of full-dose reteplase on coagulation activation markers with those of half-dose reteplase combined with full-dose abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist, during the early phase after acute myocardial infarction.
authors.affiliation: Division of Cardiology, Ospedale Niguarda, Milan, Italy. ARDIS001@planet.it
authors.forename: Piera Angelica
authors.initials: PA
authors.lastname: Merlini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Repetto
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Andreoli
authors.forename: Silvio
authors.initials: S
authors.lastname: Ricci
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lombardi
authors.forename: Angelo
authors.initials: A
authors.lastname: Finardi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Dipasquale
authors.forename: Monica
authors.initials: M
authors.lastname: Lamponi
authors.forename: Pier Mannuccio
authors.initials: PM
authors.lastname: Mannucci
authors.forename: Diego
authors.initials: D
authors.lastname: Ardissino
mesh_terms: D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007124:Immunoenzyme Techniques; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D015539:Platelet Activation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011516:Prothrombin / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013917:Thrombin / Q000096:biosynthesis*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D011516:Prothrombin; D006493:Heparin; C087896:reteplase; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D000077284:Abciximab